Document is current
Any future updates will be listed below
-
Authors
Overman, Michael
Fakih, Marwan
Le, Dung
Shields, Anthony
Pedersen, Katrina
Shah, Manish
Mukherjee, Sarbajit
Faivre, Thea
Leoni, Guido
D’Alise, Anna Morena
Cotugno, Gabriella
Langone, Francesca
Capone, Stefania
Sorbo, Maria Rosaria Del
Scarselli, Elisa
Delaite, Patricia
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04041310 at ClinicalTrials.govDocuments that mention this clinical trial
Vaccines for immunoprevention of DNA mismatch repair deficient cancers
https://doi.org/10.1136/jitc-2021-004416
Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA
https://doi.org/10.1136/jitc-2020-001065
1526 Nous-209 genetic vaccine encoding shared cancer neoantigens is safe and elicits robust immune response in healthy Lynch syndrome carriers: interim results from Phase 1 cancer interception trial
https://doi.org/10.1136/jitc-2023-sitc2023.1526
Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion
https://doi.org/10.1136/jitc-2021-003480
410 Phase I interim study results of Nous-209, an off-the-shelf immunotherapy, with pembrolizumab, for the treatment of tumors with a deficiency in mismatch repair/microsatellite instability (dMMR/MSI)
https://doi.org/10.1136/jitc-2021-sitc2021.410
Results of phase I-II bridging study for Nous-209, a neoantigen cancer immunotherapy, in combination with pembrolizumab as first line treatment in patients with advanced dMMR/MSI-h colorectal cancer.
https://doi.org/10.1200/jco.2023.41.16_suppl.e14665
New emerging targets in cancer immunotherapy: the role of neoantigens
https://doi.org/10.1136/esmoopen-2020-000684
